Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Arrowhead Pharmaceuticals (ARWR) Return on Sales (2016 - 2025)

Arrowhead Pharmaceuticals' Return on Sales history spans 16 years, with the latest figure at 0.11% for Q4 2025.

  • For Q4 2025, Return on Sales rose 7019.0% year-over-year to 0.11%; the TTM value through Dec 2025 reached 0.21%, up 26003.0%, while the annual FY2025 figure was 0.04%, 17173.0% up from the prior year.
  • Return on Sales reached 0.11% in Q4 2025 per ARWR's latest filing, up from 0.06% in the prior quarter.
  • In the past five years, Return on Sales ranged from a high of 0.68% in Q1 2025 to a low of 171.7% in Q3 2024.
  • Average Return on Sales over 5 years is 17.54%, with a median of 2.26% recorded in 2021.
  • Peak YoY movement for Return on Sales: tumbled -16480bps in 2024, then soared 17176bps in 2025.
  • A 5-year view of Return on Sales shows it stood at 2.29% in 2021, then soared by 71bps to 0.67% in 2022, then tumbled by -5605bps to 38.12% in 2023, then tumbled by -84bps to 70.09% in 2024, then surged by 100bps to 0.11% in 2025.
  • Per Business Quant, the three most recent readings for ARWR's Return on Sales are 0.11% (Q4 2025), 0.06% (Q3 2025), and 6.43% (Q2 2025).